

Amendments to the Claims


This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. - 21. (Cancelled)

22. (Currently amended) A method of promoting neural growth, the method comprising delivery to a central nervous system tissue of (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane ~~or a pharmaceutically acceptable addition salt thereof.~~

23. (Currently amended) A method of stimulating regenerative growth of damaged neuronal axons in a patient with traumatic nervous system damage, the method comprising delivering directly at a traumatic lesion site in a nerve in a patient, in an amount effective to suppress Rho family member-mediated inhibition of neuronal axon growth, a Rho family antagonist that antagonizes Rho-associated kinase activity, wherein the antagonist is (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane [[:]]



(i) a compound with the structure

wherein

~~R¹ and R² are the same or different and respectively represent: hydrogen, C₁₋₁₀ alkyl, C₂₋₅ alkanoyl, formyl, C₁₋₄ alkoxy carbonyl, amidino, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylcarbonyl, or substituted or unsubstituted phenyl, phenylalkyl, benzoyl, naphthoyl, phenylalkoxy carbonyl, pyridylcarbonyl, or piperidyl, the substituent being selected from the group consisting of a halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, phenylalkyl, nitro, and amino;~~

~~R¹ and R² together form unsubstituted or substituted benzylidene, pyrrolidylidene, or piperidylidene, the substituent being selected from the group consisting of a halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, phenylalkyl, nitro, and amino, or~~

~~R¹ or R² together with the adjacent nitrogen atom form pyrrolidinyl, piperidino, piperazinyl, morpholino, thiomorpholino, or phthalimido;~~

~~R³ represents hydrogen or C₁₋₄ alkyl;~~

~~R⁴ represents hydrogen or C₁₋₄ alkyl;~~

~~R⁵ represents hydrogen, hydroxy, or C₁₋₄ alkyl, or phenyloxy;~~

~~R⁶ represents hydrogen or C₁₋₄ alkyl;~~

~~A represents single bond, C₁₋₅ straight chain alkylene, or alkylene that is substituted by C₁₋₄ alkyl, and~~

~~n represents 0 to 1, or~~

~~(ii) an optical isomer of the compound or a pharmaceutically acceptable acid addition salt of the compound.~~

24. - 27. (Cancelled)

28. (Previously presented) The method of claim 23, wherein the regenerative growth comprises a twisted path of growth past the lesion site.

29. (Previously presented) The method of claim 23, wherein the regenerative axon growth extends distal to the lesion site.

30. (Previously presented) The method of claim 23, wherein the regenerative axon growth is up to 3 millimeter (mm) past the lesion site.

31. (Previously presented) The method of claim 23, wherein the nervous system damage is selected from the group consisting of a spinal cord injury, a spinal cord lesion, and a surgical nerve lesion.

32. (Previously presented) The method of claim 23, wherein the antagonist is administered with a pharmaceutical carrier or delivery system.

33. (Currently amended) The method of claim ~~[[23]]~~ 32, wherein the carrier is a fibrin adhesive.

34. - 39. (Cancelled)